$-0.33 EPS Expected for Unum Therapeutics Inc. (UMRX)

August 12, 2018 - By Patrick Harkless

Analysts expect Unum Therapeutics Inc. (NASDAQ:UMRX) to report $-0.33 EPS on August, 13.After having $-0.66 EPS previously, Unum Therapeutics Inc.’s analysts see -50.00 % EPS growth. The stock increased 4.59% or $0.69 during the last trading session, reaching $15.72. About 674,909 shares traded or 92.13% up from the average. Unum Therapeutics Inc. (NASDAQ:UMRX) has 0.00% since August 12, 2017 and is . It has underperformed by 12.57% the S&P500.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company has market cap of $469.07 million. The Company’s lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. It currently has negative earnings. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers.

More recent Unum Therapeutics Inc. (NASDAQ:UMRX) news were published by: Benzinga.com which released: “Benzinga’s Biotech Pulse: Pfizer’s Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke …” on August 01, 2018. Also Nasdaq.com published the news titled: “Unum Therapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on August 13, 2018 …” on August 06, 2018. Globenewswire.com‘s news article titled: “Unum Therapeutics to Present at Two Upcoming Investor Conferences” with publication date: August 08, 2018 was also an interesting one.

Unum Therapeutics Inc. (NASDAQ:UMRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.